Piper Jaffray analyst William Quirk points out that the European Union announced it will issue new rules for medical devices and in vitro diagnostics in the near-to-mid term. The EU is looking to strengthen rules for clearing devices/tests for the market and increase existing device/test surveillance, Quirk tells investors in a research note. He believes the new rules should not inhibit well validated tests/devices from coming to market. As such, Quirk expects little impact to Piper's in vitro diagnostic coverage universe, namely Accelerate Diagnostics (AXDX), Becton Dickinson (BDX), Cepheid (CPHD), Hologic (HOLX), Quidel (QDEL) and Meridian Bioscience (VIVO).